Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

The UK biotech sector faces significant transition following the appointment of a new government and the departure of Science Minister Patrick Vallance, though the selection of John Healey as Chancellor provides some stability for industry stakeholders. Regional economic development remains a strategic focus, with potential for expanding clinical trial infrastructure into Northern England. Taiwan’s innovation ecosystem continues to mature, driven by strong retail investor loyalty and established firms like Pharmacentia and TLC Bioscience. In clinical developments, Biogen’s tau-targeting Alzheimer’s therapy shows mixed results, leading to a Phase 3 trial despite missing primary endpoints. Eli Lilly’s $2.8 billion acquisition of a psychedelic asset signals a major expansion into treatment-resistant depression. Meanwhile, the FDA is moving toward traditional policy communication methods and increased reliance on advisory committees to address regulatory controversies and restore scientific transparency.